Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.

Nemunaitis J, Barve M, Orr D, Kuhn J, Magee M, Lamont J, Bedell C, Wallraven G, Pappen BO, Roth A, Horvath S, Nemunaitis D, Kumar P, Maples PB, Senzer N.

Oncology. 2014;87(1):21-9. doi: 10.1159/000360993. Epub 2014 Jun 25.

PMID:
24968881
2.

Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.

Wu J, Liu S, Yu J, Zhou G, Rao D, Jay CM, Kumar P, Sanchez R, Templeton N, Senzer N, Maples P, Nemunaitis J, Brunicardi FC.

Cancer Gene Ther. 2014 Feb;21(2):48-53. doi: 10.1038/cgt.2013.84. Epub 2014 Jan 24. Review.

PMID:
24457987
3.

Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine.

Jay CM, Ruoff C, Kumar P, Maass H, Spanhel B, Miller M, Arrington A, Montalvo N, Gresham V, Rao DD, Evans C, Wang Z, Brunicardi FC, Liu SH, Zhou G, Senzer N, Nemunaitis J, King L, Weeks B, Clubb FJ, Fossum TW, Maples PB.

Cancer Gene Ther. 2013 Dec;20(12):683-9. doi: 10.1038/cgt.2013.68. Epub 2013 Nov 29.

PMID:
24287722
4.

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.

Nemunaitis J, Senzer N, Olivares J, Kumar P, Barve M, Kuhn J, Nemunaitis T, Magee M, Yu Y, Wallraven G, Pappen BO, Maples PB.

Gene Ther. 2013 Sep;20(9):875-9. doi: 10.1038/gt.2013.9. Epub 2013 Mar 7.

PMID:
23466552
5.

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.

Simmons O, Maples PB, Senzer N, Nemunaitis J.

ISRN Oncol. 2012;2012:247657. doi: 10.5402/2012/247657. Epub 2012 Mar 11.

6.

Defining the "normal" postejaculate urinalysis.

Mehta A, Jarow JP, Maples P, Sigman M.

J Androl. 2012 Sep-Oct;33(5):917-20. Epub 2012 Jan 26.

PMID:
22282438
7.

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J.

Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20.

8.

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.

Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C, Kumar P, Pappen BO, Rao DD, Templeton NS, Daniels EQ, Webb C, Monsma D, Scott S, Dylewski D, Frieboes HB, Brunicardi FC, Senzer N, Maples PB, Nemunaitis J, Tong AW.

DNA Cell Biol. 2011 Sep;30(9):715-26. doi: 10.1089/dna.2011.1240. Epub 2011 May 25.

PMID:
21612405
9.

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.

Nemunaitis G, Jay CM, Maples PB, Gahl WA, Huizing M, Yardeni T, Tong AW, Phadke AP, Pappen BO, Bedell C, Allen H, Hernandez C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J.

Hum Gene Ther. 2011 Nov;22(11):1331-41. doi: 10.1089/hum.2010.192. Epub 2011 Apr 25.

10.

Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.

Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J.

Clin Cancer Res. 2011 Jan 1;17(1):183-92. doi: 10.1158/1078-0432.CCR-10-2195.

11.

Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.

Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, Yu Y, Haddock C, Jay C, Phadke AP, Chen S, Kuhn J, Dylewski D, Scott S, Monsma D, Webb C, Tong A, Shanahan D, Nemunaitis J.

Cancer Gene Ther. 2010 Nov;17(11):780-91. doi: 10.1038/cgt.2010.35. Epub 2010 Jul 2.

PMID:
20596090
12.

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy.

Nemunaitis G, Maples PB, Jay C, Gahl WA, Huizing M, Poling J, Tong AW, Phadke AP, Pappen BO, Bedell C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J.

J Gene Med. 2010 May;12(5):403-12. doi: 10.1002/jgm.1450.

PMID:
20440751
13.

Hereditary Inclusion Body Myopathy (HIBM2).

Jay CM, Levonyak N, Nemunaitis G, Maples PB, Nemunaitis J.

Gene Regul Syst Bio. 2009 Oct 21;3:181-90.

14.

Development and validation of a low-literacy Chronic Obstructive Pulmonary Disease knowledge Questionnaire (COPD-Q).

Maples P, Franks A, Ray S, Stevens AB, Wallace LS.

Patient Educ Couns. 2010 Oct;81(1):19-22. doi: 10.1016/j.pec.2009.11.020. Epub 2009 Dec 30.

PMID:
20044232
15.

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y, Fujiwara T.

Mol Ther. 2010 Feb;18(2):429-34. doi: 10.1038/mt.2009.262. Epub 2009 Nov 24.

16.

Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2.

Phadke AP, Jay C, Chen SJ, Haddock C, Wang Z, Yu Y, Nemunaitis D, Nemunaitis G, Templeton NS, Senzer N, Maples PB, Tong AW, Nemunaitis J.

Gene Regul Syst Bio. 2009 May 8;3:89-101.

17.

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H.

Cancer Gene Ther. 2009 Aug;16(8):620-4. doi: 10.1038/cgt.2009.15. Epub 2009 Mar 13.

PMID:
19287371
18.

Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.

Tong AW, Jay CM, Senzer N, Maples PB, Nemunaitis J.

Curr Gene Ther. 2009 Feb;9(1):45-60. Review.

PMID:
19275571
19.

Emergency use regulatory approval process for experimental gene-based therapy.

Wallraven G, Maples PB, Nemunaitis J.

J Clin Oncol. 2008 Nov 20;26(33):5488-9. doi: 10.1200/JCO.2008.19.3334. Epub 2008 Oct 20. No abstract available.

PMID:
18936466
20.

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ.

J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.

PMID:
18802154
21.

Stathmin 1: a novel therapeutic target for anticancer activity.

Rana S, Maples PB, Senzer N, Nemunaitis J.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1461-70. doi: 10.1586/14737140.8.9.1461. Review.

PMID:
18759697
22.

Compassionate approval process for experimental gene-based products.

Wallraven G, Nemunaitis JJ, Maples PB.

J Clin Oncol. 2008 Apr 10;26(11):1899-900. doi: 10.1200/JCO.2008.16.2156. No abstract available.

PMID:
18398156
23.

Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2).

Jay C, Nemunaitis G, Nemunaitis J, Senzer N, Hinderlich S, Darvish D, Ogden J, Eager J, Tong A, Maples PB.

Gene Regul Syst Bio. 2008 Jun 20;2:243-52.

24.

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.

Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, Sands B, Maples P, Tong AW.

Cancer Gene Ther. 2007 Nov;14(11):885-93. Epub 2007 Aug 17.

PMID:
17704755
25.

Proof concept for clinical justification of network mapping for personalized cancer therapeutics.

Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A, Kuhn J, Lamont J, Nemunaitis M, Rao D, Zhang YA, Zhou Y, Vorhies J, Maples P, Hill C, Shanahan D.

Cancer Gene Ther. 2007 Aug;14(8):686-95. Epub 2007 Jun 1.

PMID:
17541424
26.

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.

Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H.

J Clin Oncol. 2006 Oct 10;24(29):4721-30. Epub 2006 Sep 11.

PMID:
16966690
27.

Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy.

Parsons JK, Marschke P, Maples P, Walsh PC.

Urology. 2004 Nov;64(5):987-90.

PMID:
15533491
28.

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K.

J Natl Cancer Inst. 2004 Feb 18;96(4):326-31.

PMID:
14970281
29.

Potential clinical application of antioncogene ribozymes for human lung cancer.

Tong AW, Zhang YA, Cunningham C, Maples P, Nemunaitis J.

Clin Lung Cancer. 2001 Feb;2(3):220-6.

PMID:
14700482
30.

The Bloxsom air lock: a historical perspective.

Kendig JW, Maples PG, Maisels MJ.

Pediatrics. 2001 Dec;108(6):E116.

PMID:
11731643
31.

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D.

Gene Ther. 2001 May;8(10):746-59.

32.

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D.

Cancer Res. 2000 Nov 15;60(22):6359-66.

33.

Cellular immune profile of patients with advanced cancer before and after taxane treatment.

Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J.

Am J Clin Oncol. 2000 Oct;23(5):463-72.

PMID:
11039505
34.

A closed culture system for the ex vivo transduction and expansion of human T lymphocytes.

Robinet E, Certoux JM, Ferrand C, Maples P, Hardwick A, Cahn JY, Reynolds CW, Jacob W, Hervé P, Tiberghien P.

J Hematother. 1998 Jun;7(3):205-15.

PMID:
9621254
35.

Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.

Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI.

Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12133-8.

36.

Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow.

Smith SL, Bender JG, Maples PB, Unverzagt K, Schilling M, Lum L, Williams S, Van Epps DE.

Exp Hematol. 1993 Jul;21(7):870-7.

PMID:
7686502
37.
38.

Differential expression of alpha- and beta-globin genes in erythroleukemic cell lines.

Beru N, Maples PB, Hermine O, Goldwasser E.

Mol Cell Biol. 1990 Jul;10(7):3591-5.

39.

Determination of hemoglobin expression patterns in erythroid cells of Rana catesbeiana tadpoles.

Maples PB, Palmer JC, Broyles RH.

Comp Biochem Physiol B. 1988;91(4):755-62.

PMID:
3265661
40.

In vivo regulation of hemoglobin phenotypes of developing Rana catesbeiana.

Maples PB, Palmer JC, Broyles RH.

Dev Biol. 1986 Oct;117(2):337-41.

PMID:
3489649
41.

Embryonic and larval hemoglobins during the early development of the bullfrog, Rana catesbeiana.

Maples PB, Dorn AR, Broyles RH.

Dev Biol. 1983 Apr;96(2):515-9.

PMID:
6601035
42.

Improved polyacrylamide gel electrophoresis with different amino acids as the trailing constituent.

Parkinson AM, Dorn AR, Maples PB, Broyles RH.

Anal Biochem. 1981 Oct;117(1):6-11. No abstract available.

PMID:
6976136
43.

Two erythropietic microenvironments and two larval red cell lines in bullfrog tadpoles.

Broyles RH, Johnson GM, Maples PB, Kindell GR.

Dev Biol. 1981 Jan 30;81(2):299-314. No abstract available.

PMID:
6970686

Supplemental Content

Loading ...
Support Center